Publications by authors named "T W MATTINGLY"
Estimating a Drug's Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold.
Appl Health Econ Health Policy
November 2024
Article Synopsis
- Many cost-effectiveness analyses of pharmaceuticals ignore future price changes that occur when generic competition enters, mainly due to uncertainty in estimating post-exclusivity prices.
- The study investigates whether a drug's post-loss-of-exclusivity price can be reliably estimated using its cost of goods sold (COGS) by analyzing manufacturer profit margins and engaging stakeholders.
- Results show that COGS were successfully estimated for 2168 drugs, with a median price of $0.10 per tablet/capsule, leading to a method to estimate future prices that could enhance cost-effectiveness evaluations.
Background: Underlying intracranial stenosis is the most common cause of failed mechanical thrombectomy in acute ischemic stroke patients with large vessel occlusion. Adjunct emergent stenting is sometimes performed to improve or maintain reperfusion, despite limited data regarding its safety or efficacy.
Methods: We conducted a prospective multicenter observational international cohort study.
Article Synopsis
- Huntington's disease (HD) imposes high financial burdens on patients and caregivers, with costs increasing significantly as the disease progresses through its stages.
- A systematic review yielded five relevant studies, highlighting that annual outpatient costs are about 2.5 times greater than inpatient costs during early and middle HD stages, and that caregiver costs are the most substantial expense, ranging from $6,041 to $133,200 based on disease stage.
- Outpatient care is crucial, especially in earlier stages, as all associated costs rise sharply in later stages, indicating the heavy economic impact on both patients and their caregivers.